CoChat
Sign Up
Cited by 94

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

Li, Xiao-Feng, Dong, Hao-Long, Wang, Hong-Jiang, Huang, Xing-Yao, Qiu, Ye-Feng, Ji, Xue, Ye, Qing, Li, Chunfeng, Liu, Yang, Deng, Yong-Qiang, Jiang, Tao, Cheng, Gong, Zhang, Fu-Chun, Davidson, Andrew D., Song, Ya-Jun, Shi, Pei-Yong, Qin, Cheng-Feng·2018·Nature Communications
DOI 10.1038/s41467-018-02975-wPMC PMC5813210
Open this paper in CoChat — free account

Abstract

The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-02975-w

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 65

  1. Cao-Lormeau, V.-M. et al. Guillain-Barré syndrome outbreak associated with zika virus infection in french polynesia: a case-control study. Lancet 387, 1531–1539 (2016). · DOI
  2. D’Ortenzio, E. et al. Evidence of sexual transmission of zika virus. N. Engl. J. Med. 374, 2195–2198 (2016). · DOI
  3. Richner, J. M. et al. Modified mRNA vaccines protect against zika virus infection. Cell 168, 1114–1125.e1110 (2017). · DOI · Paper page
  4. Griffin, B. D. et al. DNA vaccination protects mice against zika virus-induced damage to the testes. Nat. Commun. 8, 15743 (2017). · DOI
  5. Larocca, R. A. et al. Vaccine protection against zika virus from brazil. Nature 536, 474–478 (2016). · DOI
  6. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against zika virus challenge in rhesus monkeys. Science 353, 1129–1132 (2016). · DOI
  7. Dowd, K. A. et al. Rapid development of a DNA vaccine for zika virus. Science 354, 237–240 (2016). · DOI
  8. Shan, C. et al. A single-dose live-attenuated vaccine prevents zika virus pregnancy transmission and testis damage. Nat. Commun. 8, 676 (2017). · DOI
  9. Gaudinski, M. R. et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet https://doi.org/10.1016/S0140-6736(17)33105-7 (2017). · DOI
  10. Tebas, P. et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine - preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1708120 (2017). · DOI
  11. Hombach, J., Solomon, T., Kurane, I., Jacobson, J. & Wood, D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23, 5205–5211 (2005). · DOI
  12. Kreil, T. R., Burger, I., Bachmann, M., Fraiss, S. & Eibl, M. M. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin. Exp. Immunol. 110, 358–361 (1997). · DOI
  13. Mason, R. A., Tauraso, N. M., Spertzel, R. O. & Ginn, R. K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25, 539–544 (1973). · DOI
  14. Turtle, L. et al. Human T cell responses to Japanese encephalitis virus in health and disease. J. Exp. Med. 213, 1331–1352 (2016). · DOI
  15. Watson, A. M., Lam, L. K., Klimstra, W. B. & Ryman, K. D. The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+but not CD8+T cells. PLoS Pathog. 12, e1005786 (2016). · DOI
  16. Yauch, L. E. et al. CD4+T cells are not required for the induction of dengue virus-specific CD8+T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185, 5405–5416 (2010). · DOI
  17. Richner, J. M. et al. Vaccine mediated protection against zika virus-induced congenital disease. Cell 170, 273–283 e212 (2017). · DOI · Paper page
  18. Shan, C. et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat. Med. 23, 763–767 (2017). · DOI
  19. Monath, T. P. et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 33, 62–72 (2015). · DOI
  20. Chokephaibulkit, K., Houillon, G., Feroldi, E. & Bouckenooghe, A. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV(R)) in children. Expert. Rev. Vaccin. 15, 153–166 (2016). · DOI
  21. Guy, B. & Jackson, N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat. Rev. Microbiol. 14, 45–54 (2016). · DOI
  22. Osorio, J. E., Wallace, D. & Stinchcomb, D. T. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert. Rev. Vaccin. 15, 497–508 (2016). · DOI
  23. Whitehead, S. S. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? Expert Rev. Vaccines 15, 509–517 (2016). · DOI
  24. Yu, Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 28, 3635–3641 (2010). · DOI
  25. Bista, M. B. et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358, 791–795 (2001). · DOI
  26. Hennessy, S. et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347, 1583–1586 (1996). · DOI
  27. Kumar, R., Tripathi, P. & Rizvi, A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N. Engl. J. Med. 360, 1465–1466 (2009). · DOI
  28. Li, X. F. et al. A chimeric dengue virus vaccine using japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J. Virol. 87, 13694–13705 (2013). · DOI
  29. Shan, C. et al. An infectious cDNA clone of zika virus to study viral virulence, mosquito transmission, and antiviral inhibitors. Cell Host Microbe 19, 891–900 (2016). · DOI
  30. Lazear, H. M. et al. A mouse model of zika virus pathogenesis. Cell Host Microbe 19, 720–730 (2016). · DOI · Paper page
  31. Zhang, N. N. et al. Characterization of the contemporary Zika virus in immunocompetent mice. Hum. Vaccin. Immunother. 12, 3107–3109 (2016). · DOI
  32. Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 7, 12204 (2016). · DOI
  33. Li, X. F. et al. Characterization of a 2016 clinical isolate of zika virus in non-human primates. EbioMedicine 12, 170–177 (2016). · DOI
  34. Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22, 1448–1455 (2016). · DOI
  35. Beck, A. S. & Barrett, A. D. Current status and future prospects of yellow fever vaccines. Expert. Rev. Vaccin. 14, 1479–1492 (2015). · DOI
  36. Guirakhoo, F. et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78, 4761–4775 (2004). · DOI
  37. Dowd, K. A. et al. Broadly neutralizing activity of zika virus-immune sera identifies a single viral serotype. Cell Rep. 16, 1485–1491 (2016). · DOI · Paper page
  38. Elong Ngono, A. et al. Mapping and role of the CD8+T cell response during primary zika virus infection in mice. Cell Host Microbe 21, 35–46 (2017). · DOI
  39. Manangeeswaran, M., Ireland, D. D. & Verthelyi, D. Zika (PRVABC59) infection is associated with T cell infiltration and neurodegeneration in CNS of immunocompetent neonatal C57Bl/6 Mice. PLoS Pathog. 12, e1006004 (2016). · DOI
  40. Guy, B. et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26, 5712–5721 (2008). · DOI
  41. Zhang, F. C., Li, X. F., Deng, Y. Q., Tong, Y. G. & Qin, C. F. Excretion of infectious Zika virus in urine. Lancet Infect. Dis. 16, 641–642 (2016). · DOI
  42. Bardina, S. V. et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356, 175–180 (2017). · DOI
  43. Li, C. et al. Zika virus disrupts neural progenitor development and leads to microcephaly in mice. Cell Stem Cell 19, 120–126 (2016). · DOI · Paper page
  44. Gunther, V. J. et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29, 3895–3904 (2011). · DOI
  45. Li, X. F. et al. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2. J. Gen. Virol. 94, 2700-2709 (2013). · DOI
  46. Yuan, L. et al. A single mutation in the prM protein of Zika virus contributes to fetal microcephaly. Science 358, 933–936 (2017). · DOI
  47. Wang, H. J. et al. Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice. Vaccine 32, 949–956 (2014). · DOI
  48. Eckels, K. H. et al. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 6, 513–518 (1988). · DOI
  49. Sumiyoshi, H., Tignor, G. H. & Shope, R. E. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J. Infect. Dis. 171, 1144–1151 (1995). · DOI
  50. Wen, J. et al. Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+T cells. Nat. Microbiol. 2, 17036 (2017). · DOI
  51. Hirsch, A. J. et al. Zika Virus infection of rhesus macaques leads to viral persistence in multiple tissues. PLoS Pathog. 13, e1006219 (2017). · DOI
  52. Quick, J. et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat. Protoc. 12, 1261–1276 (2017). · DOI · Paper page
  53. Ornelas, A. M. et al. Immune activation in amniotic fluid from Zika virus-associated microcephaly. Ann. Neurol. 81, 152–156 (2017). · DOI
  54. Chen, H. R. et al. Dengue virus nonstructural protein 1 induces vascular leakage through macrophage migration inhibitory factor andautophagy. PLoS Negl. Trop. Dis. 10, e0004828 (2016). · DOI
  55. Chuang, Y. C. et al. Macrophage migration inhibitory factor induced by dengue virus infection increases vascular permeability. Cytokine 54, 222–231 (2011). · DOI
  56. Harenberg, A. et al. Cytokine profile of children hospitalized with virologically-confirmed dengue during two Phase III Vaccine Efficacy Trials. PLoS Negl. Trop. Dis. 10, e0004830 (2016). · DOI
  57. Glass, W. G. et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202, 1087–1098 (2005). · DOI
  58. Glass, W. G. et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35–40 (2006). · DOI
  59. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016). · DOI
  60. Li, S. H. et al. Development and characterization of the replicon system of japanese encephalitis live vaccine virus SA14-14-2. Virol. J. 10, 64 (2013). · DOI
  61. Han, J. F. et al. Immunization with truncated envelope protein of Zika virus induces protective immune response in mice. Sci. Rep. 7, 10047 (2017). · DOI
  62. Hamilton, M. A., C., R. R. & V., T. R. Trimmed Spearman-Karber method for estimating median lethal concentration in toxicity bioassays. Environ. Sci. Technol. 11, 714–719 (1977). · DOI
  63. Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493–497 (1938).
  64. Liu, Y. et al. Evolutionary enhancement of zika virus infectivity in Aedes aegypti mosquitoes. Nature 545, 482–486 (2017). · DOI
  65. Dang, J. et al. Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. Cell Stem Cell 19, 258–265 (2016). · DOI · Paper page

Cited by

Sorted by citations

See all 94

Metadata

Authors
Li, X.-F., Dong, H.-L., Wang, H.-J., Huang, X.-Y., Qiu, Y.-F., Ji, X., Ye, Q., Li, C., Liu, Y., Deng, Y.-Q., Jiang, T., Cheng, G., Zhang, F.-C., Davidson, A. D., Song, Y.-J., Shi, P.-Y., & Qin, C.-F.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2018-02-14
Volume
9
Issue
1
ISSN
2041-1723
DOI
10.1038/s41467-018-02975-w
PMC
PMC5813210
Cited by
94
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review